https://www.pharmaceutical-technology.com/data-insights/jk-07-salubris-biotherapeutics-systolic-heart-failure-likelihood-of-approval/
JK-07 is under clinical development by Salubris Biotherapeutics and currently in Phase II for Systolic Heart Failure.
systolic heart failurejksalubrisbiotherapeuticslikelihood